May 16, 2018 — Accuray Inc. signed a multi-system, multi-hospital agreement with Mercy for the acquisition of Accuray Radixact and CyberKnife M6 radiation therapy systems to expand access to advanced, life-saving technology for more cancer patients. The next-generation systems will replace existing Accuray devices as well as competitive conventional linear accelerators. The order was entered into backlog during the company's fourth fiscal quarter which ends June 30, 2018.
Mercy cares for millions of patients annually across four states and was recently named one of the top five large U.S. health systems by IBM Watson Health for the third consecutive year. It is the first health system in Missouri to acquire the Radixact and CyberKnife M6 Systems. The agreement between Mercy and Accuray for these systems was reached through negotiations with healthcare supply chain management company ROi.
"Mercy partnered with Accuray because we believe the company's radiation therapy systems offer an advanced and differentiated approach to treating cancer that provides clinical and financial value to our patients, clinical teams and hospitals, and reinforces our reputation as go-to providers for exceptional cancer care," said Steve Mackin, president of Mercy Hospital St. Louis and co-executive sponsor of Mercy's cancer care steering committee. "The Radixact Systems will ensure our patients have access to the most advanced radiotherapy options and provide our large oncology program with meaningful clinical and operational enhancements compared to our current TomoTherapy Systems, allowing our team to confidently deliver very accurate treatments in standard radiation therapy treatment times, while expanding the types of cases we are able to treat. The upgrade of our CyberKnife System will also increase our teams' efficiency and effectiveness, facilitating the delivery of highly precise radiosurgery and stereotactic body radiation therapy treatments to more patients each day."
For more information: www.accuray.com
June 17, 2022 
